Tumor Biology

, Volume 35, Issue 3, pp 2437–2444 | Cite as

EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases

  • Dongdong Luo
  • Xin Ye
  • Zheng Hu
  • Kaiwen Peng
  • Ye Song
  • Xiaolu Yin
  • Guanshan Zhu
  • Qunsheng Ji
  • Yuping Peng
Research Article


Brain metastasis (BM) is a leading cause of death in patients with non-small cell lung cancer (NSCLC). EGFR mutations in primary NSCLC lesions have been associated with sensitivity to EGFR tyrosine kinase inhibitor (TKI). Therefore, it has become important to understand EGFR mutation status in BM lesions of NSCLC, and its clinical implications. BM samples of 136 NSCLC patients from South China, in which 15 had paired primary lung tumors, were retrospectively analyzed for EGFR mutation by amplification mutation refractory system (ARMS). Effect of BM EGFR mutations on progression-free survival (PFS) and overall survival (OS) was evaluated by Kaplan–Meier curves and log-rank test. EGFR mutations were detected in 52.9 % (72 of 136) of the BM lesions, with preference in female and never-smokers. A concordance rate of 93.3 % (14 of 15) was found between the primary NSCLC and corresponding BM. Positive prediction value of testing primary NSCLCs for BM EGFR mutation is 100.0 %, and negative prediction value is 87.5 %. Median PFS of BM surgery was 12 and 10 months (P = 0.594) in the wild-type and mutant group, respectively. Median OS of BM surgery was 24.5 and 15 months (P = 0.248) in the wild-type and mutant group, respectively. In conclusion, EGFR mutation status is highly concordant between the primary NSCLC and corresponding BM. The primary NSCLC could be used as surrogate samples to predict EGFR mutation status in BM lesions or vice versa. Moreover, EGFR mutations showed no significant effect on PFS or OS of NSCLCs with BM.

Key words

Brain metastasis EGFR mutations Non-small cell lung cancer 


Conflicts of interest



  1. 1.
    Han KY, Gu X, Wang HR, Liu D, Lv FZ, Li JN. Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer. Tumor Biol. 2013;34(2):821–5.CrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277–300.PubMedCrossRefGoogle Scholar
  3. 3.
    Merchut MP. Brain metastases from undiagnosed systemic neoplasms. Arch Intern Med. 1989;149(5):1076–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Sorensen JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol. 1988;6(9):1474–80.PubMedGoogle Scholar
  5. 5.
    Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.PubMedCrossRefGoogle Scholar
  6. 6.
    Porta R, Sanchez-Torres JM, Paz-Ares L, Massuti B, Reguart N, Mayo C, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37(3):624–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Paz-Ares L, Soulieres D, Melezinek I, Moecks J, Keil L, Mok T, et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med. 2010;14(1–2):51–69.PubMedCrossRefGoogle Scholar
  8. 8.
    Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67.PubMedCrossRefGoogle Scholar
  9. 9.
    Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009;65(3):351–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Ni SS, Zhang J, Zhao WL, Dong XC, Wang JL. ADAM17 is overexpression in non-small-cell lung cancer and its expression correlates with poor patients survival. Tumor Biol. 2013;34(3):1813–8.CrossRefGoogle Scholar
  11. 11.
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer. 2006;119(6):1491–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Gow CH, Chang YL, Hsu YC, Tsai MF, Wu CT, Yu CJ, et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol. 2009;20(4):696–702.PubMedCrossRefGoogle Scholar
  14. 14.
    Cortot AB, Italiano A, Burel-Vandenbos F, Martel-Planche G, Hainaut P. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer. 2010;116(11):2682–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Daniele L, Cassoni P, Bacillo E, Cappia S, Righi L, Volante M, et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol. 2009;4(6):684–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, et al. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res. 2009;15(15):4829–37.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Bai H, Wang Z, Wang Y, Zhuo M, Zhou Q, Duan J, et al. Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. PLoS One. 2013;8(2):e54170.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res. 2002;8(11):3496–502.PubMedGoogle Scholar
  19. 19.
    Zhang J, Ni SS, Zhao WL, Dong XC, Wang JL. High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma. Tumor Biol. 2013;34(4):2397–401.CrossRefGoogle Scholar
  20. 20.
    Shukuya T, Takahashi T, Naito T, Kaira R, Ono A, Nakamura Y, et al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer. 2011;74(3):457–61.PubMedCrossRefGoogle Scholar
  21. 21.
    Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, et al. EGFR mutation status and survival after diagnosis of brain metastasis in cell lung cancer. Neuro Oncol. 2010;12(11):1193–9.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol. 2009;27(3):411–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Lee YJ, Park IK, Park MS, Choi HJ, Cho BC, Chung KY, et al. Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol. 2009;135(12):1647–54.PubMedCrossRefGoogle Scholar
  24. 24.
    Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, et al. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res. 2008;14(1):162–8.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Dongdong Luo
    • 1
    • 2
  • Xin Ye
    • 3
  • Zheng Hu
    • 1
  • Kaiwen Peng
    • 1
  • Ye Song
    • 1
  • Xiaolu Yin
    • 3
  • Guanshan Zhu
    • 3
  • Qunsheng Ji
    • 3
  • Yuping Peng
    • 1
  1. 1.Department of Neurosurgery, Nanfang HospitalSouthern Medical UniversityGuangzhouChina
  2. 2.Department of NeurosurgeryCancer Center of Guangzhou Medical UniversityGuangzhouChina
  3. 3.Innovation Center China of AstraZeneca R&DShanghaiChina

Personalised recommendations